AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $36.82
- 52-wk high
- $38.37
- High
- $37.32
- 52-wk low
- $18.21
- Low
- $36.47
- Prev close
- $36.76
- Mkt cap
- $42.94B
- P/E
- 61.4x
- Volume
- 4.00M
- Fwd P/E
- 11.9x
- Beta
- 0.87
- P/S
- 2.5x
- P/B
- 5.5x
- Profit margin
- +4.1%
- Op margin
- +4.0%
- ROE
- +9.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in $0.59 a share above what analysts expected.
Earnings per share
$0.05 expected
What the street expects next
EPS expected
$0.60 to $0.74
Revenue expected
8 analysts
Last 30 days
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $4.48B | $4.71B | $3.98B | $4.14B |
| Cost of what it sold | $2.18B | $2.06B | $2.01B | $1.99B |
| Gross profit | $2.30B | $2.66B | $1.97B | $2.15B |
| What it spent | ||||
| Research and development | $256.0M | $267.0M | $222.0M | $250.0M |
| Sales and admin | $317.0M | $367.0M | $304.0M | $317.0M |
| Other operating costs | $849.0M | $1.72B | $792.0M | $1.44B |
| Total operating expenses | $1.42B | $2.35B | $1.32B | $2.00B |
| What was left | ||||
| Operating profit | $882.0M | $300.0M | $652.0M | $149.0M |
| Interest on debt | $209.0M | $292.0M | $201.0M | $200.0M |
| Profit before tax | $648.0M | $91.0M | $436.0M | -$455.0M |
| Tax | $214.0M | -$390.0M | $67.0M | $121.0M |
| Net profit | $433.0M | $480.0M | $369.0M | -$576.0M |
| EBITDA | $1.10B | $632.0M | $877.0M | -$19.0M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Leerink Partners Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)
BullishSep 9Leerink Partners Initiates Coverage on Teva Pharmaceutical Industries With Outperform Rating, $45 Price Target
BullishSep 9Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD Takes $33.80 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA
Leans bullishSep 9Nykredit A S Purchases New Position in Teva Pharmaceutical Industries Ltd. $TEVA
Leans bullishSep 6Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $48.00 at UBS Group
BullishSep 4Teva Ukraine warehouse hit twice in Russian attack, raising supply concerns
Leans bearishSep 4Teva Advances NYSE Listing With ADS Exchange Plan
BullishSep 3Teva's immune disorder drug meets main goal in mid-stage trial
BullishSep 2
Macro
33 macro signals shaping TEVA right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results